The effects of 15-LO inhibition on neurite protection and prevention of neuronal loss in vitro were assessed along with the ability of PTC-041 to mitigate α-synuclein pathology and rescue motor defects in preclinical models of PD. This evidence concerns the gene SNCA and Parkinson disease.